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24 Abstract
25 Background:  HIV treatment guidelines have traditionally recommended that all HIV-positive 
26 individuals are tested for evidence of drug resistance prior to starting ART. Testing for 
27 resistance to reverse transcriptase inhibitors (RTI) and protease inhibitors (PI) is well 
28 established in routine care. However, testing for integrase strand transfer inhibitors (InSTI) 
29 resistance is less consistent.
30 Objectives: To inform treatment guidelines by determining the prevalence of InSTI resistance in 
31 a national cohort of recently infected individuals.
32 Patients and methods: Recent (within 4 months) HIV-1 infections were identified using a 
33 Recent Infection Testing Algorithm of new HIV-1 diagnoses in the UK. Resistance-associated 
34 mutations (RAMs) in integrase, protease and RT were detected by ultradeep sequencing which 
35 allows for the sensitive estimation of the frequency of each resistant variant in a sample.  
36 Results: The analysis included 655 randomly selected individuals (median age 33 years, 95% 
37 male, 83% men who have sex with men, 78% white) sampled in 2014 to 2016 and determined 
38 to have a recent infection. These comprised 320, 138 and 197 samples from 2014, 2015 and 
39 2016, respectively. None of the samples had major InSTI RAMs occurring at high variant 
40 frequency (≥20%). A subset (25/640, 3.9%) had major InSTI RAMs occurring only as low-
41 frequency variants (2-20%). In contrast, 47/588 (8.0%) had major RTI and PI RAMs at high 
42 frequency.
43 Conclusions: Between 2014 and 2016, major InSTI RAMs were uncommon in adults with 
44 recent HIV-1 infection, only occurring as low-frequency variants of doubtful clinical significance. 
45 Continued surveillance ofTesting newly diagnosed patients for evidence of transmitted InSTI 
46 resistance is recommended to informunlikely to be of clinical practicebenefit at present.
47
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48 Introduction
49 In 2007, raltegravir was the first integrase strand transfer inhibitor (InSTI) introduced into clinical 
50 practice, initially for treatment-experienced HIV-positive patients requiring rescue therapy1 and 
51 two years later for all patients including those who are treatment-naïve. RAL was followed by 
52 elvitegravir in 2012 as part of a fixed dose, single tablet combination (Stribild) that includes the 
53 booster cobicistat, emtricitabine and tenofovir disoproxil fumarate. Elvitegravir was subsequently 
54 reformulated in combination with tenofovir alafenamide instead of tenofovir disoproxil fumarate 
55 (Genvoya). Second-generation InSTIs comprise dolutegravir, which was approved in 2013, and 
56 more recently bictegravir coformulated with tenofovir alafenamide and emtricitabine (Biktarvy), 
57 which was approved in 2018.2 Large clinical trials have demonstrated that the second-
58 generation InSTIs are potent suppressors of HIV replication and have good safety and high 
59 genetic barriers to the emergence of drug resistance.3-6 These features make them the 
60 preferred third agent for starting antiretroviral therapy (ART) in combination with a backbone of 
61 two nucleoside reverse transcriptase inhibitors (NRTIs).7 8 First-line regimens based on non-
62 nuclease reverse transcriptase inhibitors (NNRTIs) or boosted protease inhibitors (bPIs) are 
63 instead reserved for selected scenarios.
64 Mirroring European and American guidelines, the British HIV Association (BHIVA) guidelines for 
65 the treatment of HIV-1 positive adults recommend that resistance testing by viral partial genome 
66 sequencing be undertaken in all newly diagnosed patients prior to starting ART to allow the 
67 detection of transmitted drug resistance (TDR).7-10  Sequencing should be performed for reverse 
68 transcriptase and protease genes, based on studies showing that when the prevalence of TDR 
69 in the population exceeds a threshold of 1-5% it is cost-effective to screen patients to guide 
70 treatment selection.11 12 In the UK, the prevalence of TDR affecting NRTIs, NNRTIs or PIs 
71 peaked at ~14% in 2002 and has remained stable at 7-9% since 2006.13 14 To date, there is no 
72 recommendation for baseline integrase sequencing as little evidence exists of the transmission 
73 of InSTI resistance-associated mutations (RAMs) in the UK and worldwide.15
74 Most routine resistance testing is performed using conventional Sanger sequencing technology, 
75 which has variant frequency detection threshold of ~20% and hence fails to detect variants that 
76 are present below this threshold in a patient’s viral population.  Next generation sequencing 
77 (NGS) technologies allow the detection of variants present in a sample at frequency as low as 
78 1%.16 The clinical significance of low-frequency resistant variants remains under debate. It has 
79 been shown that low-frequency variants with mutations affecting the NNRTIs, and to a lesser 
80 extent the NRTIs, significantly reduce responses to first-line therapy with 2 NRTIs plus 1 NNRTI, 
81 while showing no appreciable effect on bPI-based regimens.17-20 However, transmission is 
82 unlikely to be a source of the large majority of these low-frequency variants in individuals who 
83 have recently acquired HIV and consequently would have minimal to no impact on treatment 
84 outcome as they would not have been selected under drug pressure.21
85 Several studies have reported no evidence of InSTI major RAMs in treatment-naïve or recently 
86 infected HIV-1 positive populations using Sanger sequencing.22-27 The few studies reporting 
87 apparent transmission of InSTI RAMs included mutations that are polymorphic among ART-
88 naïve patients (e.g. L74IM, T97A and E157Q).28 29 One notable exception is a study from 
89 Taiwan that observed InSTI major RAMs (e.g. Q148HKR and Y143R) in 1.2% of 1307 ART-
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90 naïve individuals under a specific epidemiological circumstance where there was a large 
91 reservoir of InSTI resistance among the treated population.30 
92 The UK national reference laboratory receives blood samples from half of all newly diagnosed 
93 cases of HIV-1 infection for incidence testing using a Recent Infection Testing Algorithm 
94 (RITA).31 Recently infected individuals are the most relevant population as they are treatment-
95 naïve and detection of resistance is most likely due to transmission and prior to natural decay. 
96 Using this resource, we determined the national prevalence of TDR to InSTIs, NRTI, NNRTI and 
97 bPI by performing NGS on samples from newly diagnosed patients identified as infected in the 
98 previous 4 months. The findings will inform the clinical utility of baseline resistance testing for 
99 integrase in the UK.
100 Patients and methods
101 Study population
102 The UK national reference laboratory applies recent infection testing algorithm (RITA) to new 
103 HIV-1 diagnoses as a sentinel national surveillance programme. Blood samples from ART-naïve 
104 individuals collected at HIV or Genitourinary Medicine Clinics in the UK are identified as likely 
105 recent infections (within 4 months of sample collection) using a Limiting-antigen (LAg) avidity 
106 assay with an OD index <1.5. The assay differentiates likely recent from long standing infection 
107 by the strength of HIV-specific antibody-antigen binding.32  The assay has a misclassification 
108 rate of long-standing HIV infections as recent of <1% when RITA is applied and samples close 
109 to the OD index cut-off values are more likely to be misclassified.33 The RITA algorithm also 
110 includes matching the sample to individual HIV records of the HIV and AIDS Reporting System 
111 (HARS). Individuals with an OD index <1.5 must also have a CD4+ cell count (>200 cells/mm3) 
112 and viral load (>1,000 copies/mL) to be assigned as ‘recent infections’. In 2014-2016, RITA was 
113 applied to 8,379 (47.9%) of new diagnoses and 1,765 (21.1%) were identified as recent 
114 infections (Figure 1). We randomly selected 655 (37.1%) of these plasma specimens with 
115 residual volume for NGS analysis, comprising by year 320, 138 and 197 samples collected in 
116 2014, 2015 and 2016, respectively. Linked demographic and clinical information was extracted 
117 from HARS. Prescription data were used to determine the use of InSTIs in clinical practice in 
118 England between 2010 and 2015. 
119 Next generation sequencing
120 RNA was extracted using QIAsymphony virus/pathogen DSP mini kit (Qiagen) and eluted in a 
121 final volume of 60 µl. Samples collected in 2014 were extracted using QIAsymphony 
122 virus/pathogen DSP mini kit (Qiagen) using 200 µl of plasma, eluted in a final volume of 60µL 
123 and processed using a previously described PCR amplicon-based NGS assay for protease-RT34 
124 and integrase was amplified in a nested PCR reaction. Briefly, cDNA was generated using 20 µl 
125 of RNA, Qiagen OneStep RT-PCR Kit (Qiagen) and primers H10F2 (5’-
126 GCACAYAARGGRATTGGAGGAAATGA-3’) and H10R3 (5’-
127 CCTAGTGGRATGTGTACTTCTGA-3’), both at 15 µM under the following cycling conditions: 
128 50˚C for 40 minutes, 95 ˚C for 15 minutes, 35 cycles of 95˚C for 30 seconds, 53˚C for 30 
129 seconds and 72˚C for 1 minutes with a final elongation step at 72˚C for 4 minutes. Two µl of 
130 cDNA were then used in a semi-nested PCR using Platinum Taq DNA Polymerase kit 
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131 (Invitrogen) and 100.4 µM of primer H10F2 and 401.6 µM of primer H10R2 (5’-
132 CATATGRTGYTTTACTAAACTHTTCCA-3’) under the following cycling conditions: 95˚C for 5 
133 minutes, 35 cycles at 94˚C for 30 seconds, 53˚C for 30 seconds and 72˚C for 1 minutes and 
134 final elongation step at 72˚C for 2 minutes. Amplicons for protease-RT and integrase were 
135 pooled in equimolar concentration and then sequenced as previously described.34 
136 Samples collected in 2015 and 2016 were processed using a sequence capture whole genome 
137 sequencing (WGS) assay (see supplementary files for details). Briefly, 350µl of plasma was 
138 extracted using the NucliSENS system on the easyMag platform (bioMérieux) and eluted into a 
139 volume of 25µl, all of which was subjected to DNAse digestion with 0.25U of TURBO DNase 
140 (Thermo Fisher Scientific) in 30µl reactions incubated for 30 minutes at 37°C. Digestion 
141 products were cleaned-up using 2X AMPure XP Beads (Beckman Coulter) following the 
142 manufacturer’s instructions, with a final elution volume of 10µl nuclease-free water. The 10µl 
143 volume of DNAse-digested RNA extracts were used to generate DNA libraries, using the KAPA 
144 RNA HyperPrep Kit (Roche). DNA libraries were pooled in a total of 500ng and hybridized using 
145 120-nt HIV-specific biotinylated oligonucleotide probes and NimbleGen SeqCap target 
146 enrichment reagents (Roche) following the manufacturer’s specifications. Following 
147 hybridization, the HIV DNA libraries bound to the biotinylated probes were partitioned using 
148 magnetic streptavidin-coated beads and subjected to a further 14 cycles of PCR amplification. 
149 The concentration of the final pool was quantified using the KAPA SYBR FAST Universal qPCR 
150 Kit for Illumina libraries (KAPA Biosystems) on a 7500 Real-Time PCR System (Applied 
151 Biosystems), and analysed for fragment size distribution using the High Sensitivity DNA Kit 
152 (Agilent) on a 2100 Bioanalyser Instrument, following both manufacturers’ specifications. 
153 Sequencing was performed on an Illumina MiSeq instrument using the MiSeq Reagent Kit V2 
154 (300 cycles) (Illumina) according to the manufacturer’s guidelines, with the following minor 
155 modifications. The final pool was diluted to 2nM and denatured with 0.2N sodium hydroxide for 
156 2 minutes, incubated for 4 minutes at 95°C, and diluted in kit reagent HT1 to produce 1ml of a 
157 20pM solution. These were further diluted to make 700µl of a 9pM solution, of which 10% was 
158 substituted with 12.5pM PhiX (Illumina). A total of 600μl of this final solution were loaded onto 
159 the MiSeq cartridge.
160 Bioinformatic analysis
161 MiSeq paired end FASTQs were trimmed for quality with trimmomatic (v0.39, with LEADING 
162 and TRAILING set to 30 and MINLEN to 50)35, and human reads removed through BWA 
163 (v0.7.17) mapping to the human genome (GRCh37), retaining unmapped pairs. Contigs 
164 generated from dehumanised reads by de novo assembly using SPAdes (v3.13.1)36 were split 
165 into fragments of approximately 500nt (depending on length) and BLASTed against 2,427 
166 reference genome sequences annotated and aligned by LANL (http://www.hiv.lanl.gov/). An in-
167 house Python script was used to build a draft sequence from the contigs and their locations 
168 within the genome alignment, filling gaps from the reference sequence(s) informing the flanking 
169 termini (in a fashion somewhat analogous to LASTZ). Two rounds of BWA mapping and 
170 consensus derivation (using an in-house C++ script – QuasiBAM)37 were performed to obtain 
171 the final nucleotide frequency table, from which an in-house perl script derived consensus 
172 genome sequences at 20% and 2% nucleotide frequencies at a minimum read depth of 30, the 
173 latter frequency previously established as the minimum threshold of the assay.34 
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174 The positive percent agreement (PPA) between amplicon and sequence capture methods was 
175 99.8% [99.7-99.9; 95%CI] and 99.0% [98.8-99.2] at 20% and 2% variant frequency thresholds, 
176 respectively at the nucleotide level (Tables S1 and S2, Figure S1).
177 Drug resistance analysis
178 The generated consensus sequences were analysed for surveillance drug resistance mutations 
179 (SDRMs) using the Calibrated Population Resistance (CPR) tool that uses the WHO 2009 list of 
180 SDRMs for PI and RTI, and recently proposed InSTI SDRMs list 2019: T66AIK, E92GQ, 
181 G118R, F121Y, E138AKT, G140ACS, Y143CHRS, S147G, Q148HRK, N155H, S230R and 
182 R263K.38-40 The integrase sequences were also analysed for the presence of the following InSTI 
183 accessory mutations: H51Y, Q95K, T97A, A128T, V151A, S153FY, E157Q and G163KR. These 
184 mutations have minimal, if any, effect on InSTI susceptibility when present alone but may 
185 contribute to reduced susceptibility in combination with InSTI major RAMs. For determination of 
186 mutational load, viral load and CD4+ count data was only used if performed within 30 days of 
187 the sample used for RITA and sequencing. Additional mutational load data for PI, NRTI and 
188 NNRTI was obtained from previously reported RT and protease sequencing of recently infected 
189 individuals from 2011 to 2013.34
190 Statistical analyses
191 Descriptive statistics (median and interquartile ranges) are provided for continuous variables 
192 whereas frequency distributions are provided for categorical variables. Mutational load datasets 
193 were compared using Mann-Whitney U-test with significance level set at p<0.05.
194 Sequence data
195 Consensus HIV-1 pol sequences from this study have been submitted to GenBank and may be 
196 accessed by the following accession numbers: MT570368-MT571329. 
197 Results
198 Use of InSTIs in England
199 The proportion of adults using InSTIs increased significantly from a low of 2.4% in London in 
200 2010 to between 17.4% and 25.7% in the Midlands and East of England and the North of 
201 England, respectively in 2015 (Figure 2).
202 Study population characteristics
203 The proportion of adults using InSTIs increased significantly from a low of 2.4% in London in 
204 2010 to between 17.4% and 25.7% in the Midlands and East of England and the North of 
205 England, respectively in 2015 (Figure 2).
206 Sequencing was performed on plasma samples from 655 recently infected individuals collected 
207 between 2014 and 2016. The characteristics of the study population are summarised in Table 1. 
208 The majority were male (94.5%) and of white ethnic background (77.9%) and their risk factor for 
209 HIV infection was classed as having sex with other men (82.9%). Most of the recent infections 
210 were from the London region (57.1%) and the median age of the study population was 33 years 
211 [26.5-41; IQR]. Median viral load was log 5.18 [4.61-6.03] copies/mL and median CD4+ count 
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212 was 545 [408-723] cells/µL, in keeping with recency of infection. Subtyping using the pol gene 
213 showed most individuals were infected with subtype B (67.5%).
214 Prevalence of integrase resistance-associated mutations
215 Of the 655 samples sequenced, 640 (97.7%) generated good quality integrase gene sequence 
216 data (complete gene coverage at minimum read depth of 100); 316, 132 and 192 in 2014, 2015 
217 and 2016, respectively. No InSTI major RAMs were detected in the 640 sequences as a high-
218 frequency variant (≥20%). A total of 25 (3.9%) sequences contained major InSTI major RAMs 
219 as low-frequency variants occurring at a frequency between 2% and 20% (Figure 3A). By year, 
220 18 (5.7%), 3 (2.3%) and 4 (2.1%) sequences contained InSTI major RAMs as low-frequency 
221 variants in 2014, 2015 and 2016, respectively. In contrast, 39 (6.1%) sequences contained 
222 InSTI accessory mutations as a high-frequency variant and 18 (2.8%) as a low-frequency 
223 variant (Figure 3A). By year, the number of sequences containing InSTI accessory mutations 
224 were 19 (6.0%), 11 (8.3%) and 9 (4.7%) as a high-frequency variant, and 8 (2.5%), 7 (5.3%) 
225 and 3 (1.6%) as a low-frequency variant in 2014, 2015 and 2016, respectively.
226 The InSTI major RAMs and accessory mutations detected are shown in Figure 3B. The most 
227 common InSTI major RAMs detected as low-frequency variants were E138K (8/25; 32.0%) and 
228 Q148K (7/25; 28.0%). On the other hand, the most common InSTI accessory mutation detected 
229 as a high-frequency variant was E157Q (29/39; 74.4%) whereas V151A was the most common 
230 InSTI accessory mutation detected as a low-frequency variant (5/18; 27.8%). Most of the InSTI 
231 accessory mutations present as high-frequency variants were associated with non-B subtypes 
232 (22/39; 56.4%) with the majority associated with the circulating recombinant forms CRF02_AG 
233 (n=9) and CRF06_cpx (n=8). The presence of low frequency RAMs was confirmed by read-
234 based RAM analysis using the variant frequency files produced by the QuasiBam software 
235 (Table S3).
236 Prevalence of Rreverse Ttranscriptase and Pprotease Rresistance-associated 
237 mutations
238 Of the 655 samples sequenced, 619, 593 and 588 generated good quality sequence data for 
239 protease, reverse transcriptase and both gene regions, respectively. By year, 302, 129 and 188 
240 protease, and 295, 116 and 182 RT sequences were generated for 2014, 2015 and 2016, 
241 respectively. TDR prevalence for all drug classes for the period 2014-2016 was 8.0% (47/588) 
242 for high-frequency variants and 10.9% (64/588) for low-frequency variants. TDR mutations were 
243 detected as a high-frequency variant in 15 (2.4%), 20 (3.4%) and 17 (2.9%) sequences against 
244 PIs, NRTIs and NNRTIs, respectively (Figure 4A). The overall prevalence of TDR low-
245 frequency variants against PIs, NRTIs and NNRTIs was 27 (4.4%), 29 (4.9%) and 12 (1.0%), 
246 respectively (Figure 4A, Table S3). The most common TDR mutations detected as a high-
247 frequency variant were L90M (7/15; 46.7%), T215rev (11/20; 55.0%) and K103N (12/17; 70.6%) 
248 against PIs, NRTIs and NNRTIs, respectively (Figure 4B). In contrast, the most common TDR 
249 mutations detected as a low-frequency variant were M46IL (13/27; 48.1%), D67GNE (13/29; 
250 44.8%) and G190E (6/12; 50.0%) against PIs, NRTIs and NNRTIs, respectively (Figure 4B).
251 Of the 655 sequences 581 (88.7%) generated sufficient and good quality data in all three 
252 polymerase gene regions. Two (0.3%) of the samples had a low-frequency variant InSTI major 
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253 RAM and a high-frequency variant RAM in protease or RT: Q148K + G190A (NNRTI) and E92G 
254 + T215S (NRTI). Both were subtype B. Three samples (0.5%) had a low-frequency variant InSTI 
255 major RAM (E138K) and low-frequency variant RAM in protease and/or RT: D67N (NRTI) + 
256 M46I (PI), M46I (PI) and D67G (NRTI) and they were subtype F, B and CRF01_AE, 
257 respectively.
258 Mutational load of low frequency RAMsresistance-associated mutations
259 We determined the mutational load of low-frequency RAMs as previously described.19. The 
260 median mutational load of low-frequency InSTI RAMs was 3,833 [895-14,733; IQR] copies/mL 
261 (Figure 5). The median mutational load of low-frequency InSTI RAMs was similar to that of low-
262 frequency PI and NRTI RAMs at 5,914 [1,470-31,552] and 2,706 [1,387-11,726] copies/mL, 
263 respectively. In contrast, the mutational load for low-frequency NNRTI RAMs was slightly higher 
264 and had a broad range at 10,188 [2,170-95,313] copies/mL; however, the difference wasis not 
265 statistically significant (p>0.05, Mann Whitney U test).
266 Discussion
267 Surveillance of transmitted InSTI resistance among a population of 655 recently infected 
268 individuals with recent HIV infection in the UK who were sampled between 2014 and 2016 
269 showed no evidence of transmission ofmajor InSTI major RAMs when considering mutants 
270 present at high frequency in the individuals’ samples. In contrast, at approximately 8%, the 
271 prevalence of TDR to PIs and RTIs remains steady compared to last reported figures in 2014 at 
272 approximately 8%. This prevalence is still higher than the recommended threshold of 1-5% 
273 where baseline resistance testing is considered of benefit at the population level.
274 On the other hand, accessory InSTI resistance mutations were detected as a high-frequency 
275 variants in 6.1% of the study population. The most common accessory InSTI RAMs were T97A 
276 and E157Q; both which are polymorphic and observed at a high prevalence (up to 7%) in InSTI-
277 naïve individuals infected with non-B subtypes e.g. CRF02_AG, at up to 7% prevalence. They 
278 are also selected in patients experiencing treatment failure with first-generation InSTIs, 
279 raltegravir and elvitegravir; however, they have little effect on InSTI susceptibility when present 
280 alone.41
281 Ultradeep sequencing allowed the detection of mutations below the Sanger sequencing variant 
282 frequency threshold of ~20%. Major InSTI major RAMs were detected as a low-frequency 
283 variant in 3.9% of the study population, at a variant frequency between 2% and 20%. It has 
284 been argued that the mutational load of low-frequency RAMs, especially for NNRTIs, could play 
285 a role in treatment failure.42 The mutational load of low-frequency InSTI RAMs was comparable 
286 to that of NRTI and PI RAMs, but was lower and had a very narrow range compared to that of 
287 NNRTI RAMs. Compared to the data for low-frequency NNRTI RAMs, Tthere is less compelling 
288 evidence that low-frequency PI and NRTI RAMs contribute to treatment failure.20 It is likely that 
289 the mutational load of low-frequency RAMs is associated with the impact on virus replication 
290 fitness, therefore InSTI, NRTI and PI RAMs which have a high impact on virus replication fitness 
291 are unlikely to accumulate to high absolute levels compared to NNRTI RAMs. In addition, Wwe 
292 recently showed evidence that the majority of low-frequency RAMs to PIs and RTIs in recently 
293 infected individuals are not a result of a transmission event and thus would not have been 
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294 selected under drug pressure.21 Furthermore, a recent study showed no association between 
295 the presence of low-frequency InSTI RAMs prior to initiation of treatment and treatment 
296 outcomes.43 Taken together, these data suggest that the low-frequency InSTI RAMs in recently 
297 infected individuals are less likely to affect treatment outcome especially as current second-
298 generation InSTIs, dolutegravir and bictegravir, are highly effective and have very high genetic 
299 barriers to resistance. However, the low-frequency InSTI RAMs may still have an impact in 
300 treatment-experienced individuals, those with poor adherence or those who harbour resistance 
301 to other components of their ART regimenwho have undergone treatment interruption.
302 The proportion of individuals on an ART regimen that included an InSTI was approximately 20% 
303 during the period covered by the study, as estimated using prescription data from NHS England. 
304 The use of InSTIs as part of first-line regimens is anticipated to continue to rise in the UK 
305 reflecting national and international treatment guidelines.44 The use of InSTIs in the UK 
306 increased from less than 10% in 2014 to over 20% in 2015; thus, the effect of this and further 
307 projected increases in InSTI use may not be captured in this surveillance study. Nonetheless, 
308 the virological suppression rate for people on InSTI-based therapy in the UK is very high (>95%) 
309 and the likelihood of the emergence of drug resistance for those failing dolutegravir or 
310 bictegravir plus two NRTIs in first-line ART is negligible.3 4 However, raltegravir and elvitegravir 
311 have been used for longer than dolutegravir and bictegravir in ART-naïve and ART-experienced 
312 patients and these drugs are more likely to result in treatment failure with resistance selection. 
313 Thus, these groups may have generated a pool of potential transmitters which may later 
314 contribute to transmitted InSTI resistance. All these factors necessitate continued surveillance of 
315 InSTI TDR in the coming years. 
316 Reflecting the focus on recent infection, Aanother limitation of the study is that most of the 
317 sampled population was from England, were male, of white ethnic background from Englandand 
318 whose probable route of HIV exposure was sex between men and who were infected with 
319 subtype B virus. This is because gay and bisexual men are more likely to have recently 
320 acquired infection at HIV diagnosis. Thus, these findings may not be generalizable to the whole 
321 of the UK population living with HIV, and particularly women and those infected with non-B 
322 subtypes. In addition, the frequency of InSTI use may be different in Scotland, Wales and 
323 Northern Ireland, data which was not captured in this study.
324 Two different sequencing methods were used in this study, an amplicon-based approach using 
325 gene-specific nested PCR followed by DNA library prep and a sequence capture approach 
326 which is dependent on RNA library prep followed by enrichment using HIV-1 specific probe 
327 baits. Overall the consensus sequence generated by both methods were highly concordant 
328 (>99%) using the 20% and 2% variant frequency at nucleotide level (see supplementary data). 
329 Discordances were at mixed base positions where one method detected only one of the mixed 
330 bases with a tendency for low-frequency variants detected by amplicon method being 
331 infrequently detected by sequence capture whereas the opposite was true. This could either be 
332 due an overcall of low-frequency variants by the amplicon method or a decreased sensitivity for 
333 detection of low-frequency variants by the sequence capture. This requires further investigation 
334 using standardised reference or control material with well-characterised low-frequency variants 
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335 at specific frequencies. The validation of NGS methods to accurately reflect in vivo low-
336 frequency variants is essential to determine their effect on clinical outcomes. 
337 In conclusion, this study shows no evidence of transmitted InSTI resistance in the recently 
338 infected population in the UK. However, performing baseline integrase resistance testing is still 
339 important, especially for national reference laboratories in order to provide surveillance data 
340 suggesting that baseline InSTI resistance testing is unlikely to be of clinical benefit. However, 
341 continued surveillance is recommended and possibly in selected patients in routine clinical 
342 practice. One consideration isconsidering that the use of InSTIs as part of first-line cART is 
343 anticipated to continue to increase worldwide following WHO recommendations. The large-scale 
344 use of DTG in resource-limited settings is likely to take place with limited viral load monitoring 
345 and thus could result in significant increases in transmitted InSTI resistance from a more global 
346 perspectivein the UK and low-frequency InSTI resistance was detected at 3.9%. In parallel, 
347 prospective cohort studies to assess treatment outcomes in recently infected individuals 
348 harbouring the low-frequency RAMsvariants would best inform their clinical significance and 
349 diagnostic utility. The use of WGS adopted from 2015 onwards will also be useful in analysing 
350 other regions of the HIV-1 genome that have been postulated to be involved in development of 
351 resistance to second-generation InSTI, such as envelope and 3’ polypurine tract (PPT).45 46
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Heterosexual male 48 (7.3)
Heterosexual female 33 (5.0)
IDU 3 (0.5)
Risk exposure
Other / Unknown 28 (4.3)
White 510 (77.9)
Black (African / Caribbean / Other) 41 (6.3)
Ethnicity
Other / Unknown 104 (15.9)
London 374 (57.1)
North of England 113 (17.3)
Midlands & East of England 83 (12.7)
South of England 78 (11.9)

















Complex recombinants 9 (1.4)
Age in years 33 [26.5-41]
CD4+ count (cells/mm3) 545 [408-723]b
Viral load (log10, copies/mL) 5.18 [4.61-6.03]c
549 abinary or category variables are presented as a number (% total) whereas continuous variables are 
550 presented as median (interquartile range)
551 bn=602, number of samples with CD4+ counts done within 30 days of date of collection of the sample 
552 used for RITA and sequencing
553 cn=366, number of samples with viral load done within 30 days of date of collection of the sample used for 
554 RITA and sequencing
555
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556 Figure Legends
557 Figure 1. Flow chart showing study participant selection. Patients were eligible for inclusion if 
558 they were newly diagnosed and identified to be recently infected (within 4 months of sampling) 
559 using RITA.
560 Figure 2. The proportion of people on ART including InSTI in England between 2010 and 2015. 
561 The data was estimated from ART prescribing data from NHS England and is stratified by PHE 
562 regions of London, Midlands & East of England, North of England and South of England. Data 
563 for London in 2015 does not include figures for the month of December. Hospitals in the former 
564 North West Strategic Health Authority (SHA) preferred to use RAL over bPIs as third agent for a 
565 significant portion of the survey period. Figures may include a source of over-estimation as RAL 
566 was used as first-line Post-Exposure Prophylaxis following Sexual Exposure (PEPSE). NA = 
567 data not available.
568 Figure 3. Prevalence of InSTI RAMs in recently infected individuals in the UK between 2014 
569 and 2016. Stacked column graphs showing the prevalence of InSTI major and accessory 
570 resistance (A) and types of InSTI resistance mutations (B) at high (>20%) and low (2-20%) 
571 variant frequency. This was determined from 640 integrase sequences from recently infected 
572 individuals consisting of 316, 132 and 192 sequences in 2014, 2015 and 2016, respectively. 
573 Major and accessory InSTI resistance mutations were determined using the Stanford HIV Drug 
574 Resistance Database InSTI SDRM list 2019 and InSTI accessory mutations as of October 2019.
575 Figure 4. Prevalence of PI and RTI TDR mutations in recently infected individuals in the UK 
576 between 2014 and 2016. Stacked column graphs showing the prevalence of PI and RTI TDR 
577 mutations (A) and types of PI, NRTI and NNRTI resistance mutations (B) at high (>20%) and 
578 low (2-20%) variant frequency. This was determined from 622 protease and 597 RT sequences 
579 from recently infected individuals consisting of 302, 129 and 188 protease sequences and 295, 
580 116 and 182 RT sequences in 2014, 2015 and 2016, respectively. PI, NRTI and NNRTI TDR 
581 mutations were determined using the WHO SDRM list 2019.
582 Figure 5. Mutational load of low-frequency RAMs. Box and whisker plot of mutational load of 
583 low frequency InSTI (n=14), PI (n=44), NRTI (n=28) and NNRTI (n=14) RAMs. Mutational load 
584 is defined as mutation frequency  viral load (copies/mL).
585
586
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Table S1. Comparison of amplicon and sequence capture NGS-based methods
a using the integrase gene region from 19 different samples
b positions where the two methods gav  completely different bases e.g. T vs C
c positions where one method had mixed bases whereas the other method had only one of the bases in the mixture e.g. Y vs T




Total no. of 





20% 15410 32 7 25 99.8 99.7-99.9
2% 15401 153 3 150 99.0 98.8-99.2
Variant frequency 
range
Method No. of mixed base 
sites
No. concordant in 
alternate method




SeqCap 16 11 68.8 13 81.3>20%
Amplicon 29 10 34.5 21 72.4
SeqCap 57 10 17.5 23 40.42-20%
Amplicon 116 11 9.5 14 12.1
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% in amplicon of 
2-20% VF in 
SeqCap
% in SeqCap of 2-
20% VF in 
amplicon
Figure S1. Distribution of variants at mixed base positions. 
The frequency of variants was determined for each method for 
variants detected within the 2-20% range by the alternate 
method and displayed in a box-whisker graph. This shows that 
low-frequency variants detected by the amplicon method are 
infrequently detected by the SeqCap method whereas the 
opposite is true.
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Table S3. Codon frequency of low-frequency drug resistance variants
Gene Sample ID Mutation AA:freq Codon:freq Depth
Integrase 14-0057 S147G S:84.3487, G:15.4707, AGT:84.0597, GGT:15.4587, 8306
Integrase 14-0128 E138K E:92.2577, K:7.19498, GAA:92.1551, AAA:7.18358, 8770
Integrase 14-0131 G140S G:94.5347, S:5.05922, GGC:94.3147, AGC:5.05922, 5910
Integrase 14-0144 Q148K Q:97.4224, K:2.2942, CAA:95.5735, AAA:2.2942, CAG:1.84885, 7410
Integrase 14-0159 Q148K Q:97.3832, K:2.11281, CAA:96.8599, AAA:2.11281, 5159
Integrase 14-0161 R263K R:82.5018, K:16.3036, AGA:82.2441, AAA:16.2567, 4269
Integrase 14-0186 Q148K Q:97.2064, K:2.2843, CAA:96.8394, AAA:2.2843, 13352
Integrase 14-0191 Q148K Q:97.2017, K:2.54029, CAA:96.9675, AAA:2.54029, 25194
Integrase 14-0261 Q148K Q:97.1632, K:2.2705, CAA:96.567, AAA:2.26505, 36732
Integrase 14-0280 Q148K Q:95.7972, K:2.17376, CAG:95.6766, AAG:2.17376, 29028
Integrase 14-0298 E138K E:96.9016, K:2.32711, GAA:96.6868, AAA:2.32711, 22818
Integrase 14-0302 S147G S:87.8656, G:12.0877, AGT:87.6945, GGT:12.0566, 6428
Integrase 14-0329 Q148K Q:97.1253, K:2.34673, CAA:96.7732, AAA:2.34673, 3409
Integrase 14-0395 S230R S:96.964, R:2.06878, AGC:96.8834, AGA:2.01505, 3722
Integrase 14-0416 E138K E:89.5409, K:9.57476, GAG:89.3389, AAG:9.5693, 18319
Integrase 14-0417 E92G E:93.6004, G:5.76984, GAG:93.4981, GGG:5.73835, 12704
Integrase 14-0419 E138K E:95.5778, K:3.63601, GAA:95.4206, AAA:3.62618, 10176
Integrase 14-0425 S147G S:95.7666, G:4.15528, AGT:95.5167, GGT:4.15528, 12803
Integrase 15-2792 E138K E:96.3542, K:3.64583, GAG:95.8333, AAG:3.64583, 384
Integrase 15-2828 E138K E:91.4186, K:8.53367, GAA:91.4026, AAA:8.53367, 6281
Integrase 15-3206 E138K E:97.2211, K:2.50803, GAA:97.2111, AAA:2.50803, 9968
Integrase 16-0742 G118R G:96.7391, R:3.26087, GGA:96.7391, AGA:3.26087, 92
Integrase 16-0775 Y143H Y:97.2163, H:2.67666, TAC:97.0021, CAC:2.67666, 934
Integrase 16-0830 G140S G:93.5223, S:6.17409, GGT:93.5223, AGT:6.17409, 1976
Integrase 16-0831 E138K E:94.575, K:5.42504, GAA:94.5265, AAA:5.42504, 4129
Integrase 14-0049 E157Q E:94.3676, Q:5.38094, GAA:94.3425, CAA:5.38094, 3977
Integrase 14-0103 V151A V:89.7666, A:10.069, GTA:89.2898, GCA:10.069, 12166
Integrase 14-0136 S153F S:93.7058, F:5.66108, TCT:93.5568, TTT:5.66108, 2685
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Integrase 14-0174 G163R G:96.2559, R:2.72596, GGA:95.9735, AGA:2.72596, 15224
Integrase 14-0181 E157Q E:94.8027, Q:4.96599, GAA:94.5986, CAA:4.96599, 7350
Integrase 14-0181 G163R G:97.969, R:2.00357, GGA:97.5298, AGA:2.00357, 7287
Integrase 14-0379 G163R G:95.9228, R:2.76765, GGA:95.3827, AGA:2.76765, 7407
Integrase 14-0387 V151A V:97.3938, A:2.4277, GTG:96.769, GCG:2.4277, 5602
Integrase 14-0431 A128T A:94.2695, T:5.68078, GCC:94.1866, ACC:5.68078, 24134
Integrase 15-2838 H51Y H:97.8102, Y:2.18978, CAT:97.8102, TAT:2.18978, 137
Integrase 15-2861 V151A V:93.573, A:3.15904, G:2.61438, GTA:93.573, GCA:3.15904, GGA:2.61438, 918
Integrase 15-2942 V151A V:95.4248, A:4.57516, GTG:84.9673, GTA:10.4575, GCG:4.57516, 306
Integrase 15-2950 H51Y H:92.2399, Y:7.58377, CAT:92.2399, TAT:7.58377, 567
Integrase 15-2958 V151A V:92.7253, A:4.10146, GTA:92.6606, GCA:4.10146, 9265
Integrase 15-3064 S153F S:85.4202, F:14.5798, TCT:85.4202, TTT:14.5798, 583
Integrase 15-3252 E157Q E:93.2653, Q:6.53061, GAA:93.2653, CAA:6.53061, 980
Integrase 16-0739 H51Y H:94.1402, Y:5.81341, CAT:94.0938, TAT:5.81341, 8618
Integrase 16-0804 A128T A:96.7692, T:3.20479, GCA:96.7431, ACA:3.20479, 3838
Integrase 16-0804 V151A V:93.5411, A:4.60812, M:1.75637, GTG:93.4844, GCG:4.60812, ATG:1.75637, 5295
Integrase 16-0847 H51Y H:97.764, Y:2.23602, CAT:97.764, TAT:2.23602, 805
RT 14-0111 F77L F:96.3229, L:2.47802, S:1.1191, TTC:95.8433, CTC:2.47802, TCC:1.1191, 1251
RT 14-0128 D67N D:94.9077, N:4.53875, GAT:94.8155, AAT:4.5203, 5420
RT 14-0195 M41L M:93.2409, L:5.60768, ATG:93.2409, CTG:5.60768, 4690
RT 14-0218 K65R K:96.8848, R:2.91979, AAG:96.8197, AGG:2.91979, 9213
RT 14-0232 F77L F:96.9987, L:2.43125, TTC:96.9316, CTC:2.09591, 5964
RT 14-0282 K219R K:94.1369, R:5.14612, AAA:93.9826, AGA:5.14612, 11018
RT 14-0298 D67G D:90.1886, G:9.1043, GAC:90.0265, GGC:9.1043, 6788
RT 14-0311 D67G D:96.3252, G:3.67483, GAC:96.3252, GGC:3.67483, 898
RT 14-0353 D67G D:97.2086, G:2.38127, GAC:97.1689, GGC:2.38127, 7559
RT 14-0427 D67G D:96.2117, G:3.06675, GAC:96.0914, GGC:3.06675, 1663
RT 14-0434 K65R K:97.5438, R:2.11851, AAG:97.4823, AGG:2.11851, 3257
RT 14-0436 D67G D:96.9207, G:2.69438, GAC:96.6128, GGC:2.69438, 1299
RT 14-0437 M184I M:95.5732, I:3.18471, ATG:95.5732, ATA:2.92994, 3140
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RT 14-0438 D67G D:94.6474, G:5.09771, GAC:94.4775, GGC:5.09771, 2354
RT 15-2840 D67N D:97.3847, N:2.47003, GAT:97.3847, AAT:2.47003, 2753
RT 15-2847 K219R K:96.7532, R:3.24675, AAA:96.7532, AGA:3.24675, 154
RT 15-3018 D67N D:97.7273, N:2.27273, GAT:97.7273, AAT:2.27273, 176
RT 15-3059 M184I M:96.5116, I:3.48837, ATG:96.5116, ATA:3.48837, 344
RT 15-3067 K219N K:95.5437, N:4.45633, AAA:95.5437, AAT:4.45633, 561
RT 15-3117 M184I M:93.1483, I:6.8174, ATG:93.1483, ATA:6.44056, 2919
RT 16-0741 M184I M:96.5614, I:3.42205, ATG:96.5614, ATA:3.33939, 6049
RT 16-0745 D67N D:97.4684, N:2.53165, GAT:97.4684, AAT:2.53165, 158
RT 16-0786 D67N D:94.6404, N:5.35961, GAT:94.6404, AAT:5.35961, 5075
RT 16-0799 M184I M:91.1871, I:8.74101, ATG:91.1871, ATA:8.70504, 2780
RT 16-0800 M184I M:94.3534, I:5.64663, ATG:94.3534, ATA:5.46448, 549
RT 16-0841 D67G D:85.3253, G:14.5234, GAC:85.3253, GGC:14.5234, 661
RT 16-0858 M184I M:97.9458, I:2.05423, ATG:97.9458, ATA:2.01315, 2434
RT 16-0879 M184I M:96.0673, I:3.88411, ATG:96.0673, ATA:3.83064, 20571
RT 16-0900 D67G D:92.3077, G:7.50315, GAT:92.1816, GGT:7.50315, 1586
RT 14-0080 V106A V:97.2472, A:2.67103, GTG:95.9389, GCG:2.61652, 3669
RT 14-0217 Y188H Y:94.4268, H:5.25478, TAT:94.2675, CAT:5.25478, 628
RT 14-0405 K103N K:95.2284, N:3.98034, AAA:95.1445, AAC:3.96835, 8341
RT 14-0443 K101E K:96.0389, E:3.70736, AAA:95.8416, GAA:3.70736, 7094
RT 14-0443 K103N K:82.1165, N:16.9742, AAA:81.9452, AAC:16.6974, 7588
RT 14-0443 Y188H Y:92.4967, H:7.26386, TAT:92.1951, CAT:7.25499, 11275
RT 15-2803 G190E G:97.2282, E:2.69945, GGA:97.2282, GAA:2.69945, 4149
RT 15-2837 K103N K:89.7959, N:10.2041, AAA:89.7959, AAC:10.2041, 441
RT 15-2861 G190E G:95.8559, E:4.14414, GGA:95.8559, GAA:4.14414, 1110
RT 15-3089 G190E G:80, E:19.5918, GGA:80, GAA:19.5918, 245
RT 15-3207 V106A V:89.5053, A:10.4227, GTA:89.5053, GCA:10.4227, 4164
RT 16-0745 G190E G:92.9444, E:6.3772, GGA:92.9444, GAA:6.3772, 737
RT 16-0769 G190E G:96.5877, E:3.31754, GGA:96.5877, GAA:3.31754, 2110
RT 16-0773 K101E K:94.8252, E:5.17483, AAA:94.8252, GAA:5.17483, 715
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RT 16-0845 G190E G:95.9751, E:3.85892, GGA:95.9751, GAA:3.85892, 2410
PR 14-0077 M46I M:97.0008, I:2.71159, ATG:97.0008, ATA:1.97206, 2434
PR 14-0087 V82A V:92.1878, A:7.6314, GTC:91.2339, GCC:7.60646, 16039
PR 14-0128 M46I M:94.0327, I:5.66519, ATG:94.0327, ATA:5.47635, 10591
PR 14-0142 M46I M:93.2759, I:6.37931, ATG:93.2759, ATA:6.24521, 10440
PR 14-0196 I54V I:97.2679, V:2.34663, ATC:96.9913, GTC:2.34663, 11932
PR 14-0197 M46I M:97.7584, I:2.18144, ATG:97.7584, ATA:2.16639, 6647
PR 14-0215 M46I M:92.0221, I:7.81991, ATG:92.0221, ATA:7.74092, 2532
PR 14-0220 G73S G:97.0144, S:2.83819, GGT:96.6273, AGT:2.83819, 5426
PR 14-0224 N83D N:95.1649, D:4.61019, AAC:95.1274, GAC:4.61019, 5336
PR 14-0244 M46L M:97.7225, L:2.05809, ATG:97.7225, TTG:2.02674, 9572
PR 14-0295 N83D N:96.67, D:3.14004, AAC:96.6067, GAC:3.14004, 7898
PR 14-0323 I85V I:94.8741, V:4.85126, ATT:94.5538, GTT:4.85126, 2185
PR 14-0360 I47V I:95.7078, V:3.93147, ATA:95.6898, GTA:3.93147, 5545
PR 14-0399 M46I M:96.6017, I:3.12115, ATG:96.6017, ATA:3.01971, 55204
PR 14-0405 M46L M:96.2874, L:3.18044, ATG:96.2874, TTG:3.16776, 7892
PR 14-0419 M46I M:85.6092, I:14.0484, ATG:85.6092, ATA:13.5539, 7887
PR 14-0422 V32I V:96.7893, I:3.00642, GTA:96.6871, ATA:3.00642, 6852
PR 14-0444 D30N D:88.5475, N:11.1034, GAT:88.2542, AAT:11.1034, 7160
PR 15-2892 G73S G:97.262, S:2.59003, GGT:97.2373, AGT:2.59003, 4054
PR 15-3019 V82L V:93.5012, L:6.39712, GTC:93.4856, CTC:6.39712, 12787
PR 15-3050 F53L F:84.6348, L:15.3652, TTT:84.6348, CTT:15.3652, 397
PR 16-0717 M46I M:91.4494, I:3.90283, ATG:91.4494, ATA:3.88664, 6175
PR 16-0796 M46I M:95.4325, I:4.56754, ATG:95.4325, ATA:4.56754, 1029
PR 16-0901 L76V L:96.1762, V:3.82381, TTA:96.031, GTA:3.82381, 2066
PR 16-0992 M46I M:86.7987, I:13.2013, ATG:86.7987, ATA:13.2013, 303
PR 16-1001 D30N D:95.2381, N:4.7619, GAT:95.2381, AAT:4.7619, 147
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